title: Quantified gene expression levels for phase I/II metabolizing enzyme and estrogen receptor levels in benign prostate from cohorts designated as high-risk (UK) versus low-risk (India) for adenocarcinoma at this organ site: a preliminary study.
abstract: Risk of clinically significant prostate adenocarcinoma (CaP) varies worldwide, although there is a uniform prevalence of latent disease. A hormone-responsive tissue, the prostate possesses the metabolizing capacity to biotransform a variety of environmental procarcinogens or endogenous hormones. Whether such metabolizing capacity or estrogen receptor (ER) status underlies these demographic differences in susceptibility to CaP remains unclear. With appropriate ethical permission, verified-benign tissues were obtained following transurethral resection of the prostate from a high-risk region (n = 12 UK-resident Caucasians) and a typically low-risk region (n = 14 India-resident Asians). Quantitative gene expression analysis was employed for cytochrome P450 (CYP)1B1, N-acetyltransferase (NAT)1, NAT2, catechol-O-methyl transferase (COMT), sulfotransferase (SULT)1A1, ERalpha, ERbeta and aromatase (CYP19A1). To quantify the presence or absence of CYP1B1, ERalpha or ERbeta, and to identify their in situ localization, immunohistochemistry was carried out. The two cohorts had reasonably well-matched serum levels of prostate-specific antigen or hormones. Expression levels for the candidate genes investigated were similar. However, clear differences in protein levels for CYP1B1 and ERbeta were noted. Staining for CYP1B1 tended to be nuclear-associated in the basal glandular epithelial cells, and in UK-resident Caucasian tissues was present at a higher (P = 0.006) level compared with that from India-resident Asians. In contrast, a higher level of positive ERbeta staining was noted in prostates from India-resident Asians. These study findings point to differences in metabolizing capacity and ER status in benign prostate tissues that might modulate susceptibility to the emergence of clinically significant CaP in demographically distinct populations.
authors: Centre for Biophotonics, Lancaster Environment Centre, Lancaster University, Bailrigg, UK.
authors: Paras B
authors: PB
authors: Singh
authors: Narasimhan
authors: N
authors: Ragavan
authors: Katherine M
authors: KM
authors: Ashton
authors: Prabir
authors: P
authors: Basu
authors: Sayeed M
authors: SM
authors: Nadeem
authors: Caroline M
authors: CM
authors: Nicholson
authors: R K Gopala
authors: RK
authors: Krishna
authors: Shyam S
authors: SS
authors: Matanhelia
authors: Francis L
authors: FL
authors: Martin
mesh_terms: D000230:Adenocarcinoma / Q000201:enzymology / Q000378:metabolism* / Q000473:pathology; D001483:Base Sequence; D015331:Cohort Studies; D017931:DNA Primers; D004798:Enzymes / Q000378:metabolism*; D006801:Humans; D007194:India; D008297:Male; D011467:Prostate / Q000201:enzymology / Q000378:metabolism*; D011471:Prostatic Neoplasms / Q000201:enzymology / Q000378:metabolism* / Q000473:pathology; D011960:Receptors, Estrogen / Q000378:metabolism*; D006113:United Kingdom
chemical_list: D017931:DNA Primers; D004798:Enzymes; D011960:Receptors, Estrogen